The analysts seem to think that Actelion and Cipla are the next two darlings at the Acquisition Ball. Actelion is coming off great news for two of its clinical pipeline drugs that are both touted as blockbusters. This obviously makes it attractive. But its market cap of $14.3 B also makes it somewhat challenging --- though I'm not sure why that really is the case to a Big Pocket Pharma. If Pfizer can go after AZ then certainly many other pharma companies can go after Actelion if they so choose. For its part, Actelion's CEO, Jean-Paul Clozel says that its recent success (tripling of its stock price) has shown the investment world that it is "deserving" of staying independent and that is the best course for its shareholders. I guess that depends on how big a premium someone is willing to offer, eh, Jean-Paul? See Bloomberg.
Cipla on the other hand is rumored to be a potential darling for the generics set. Not only to tap into its portfolio of product sales but also to gain a substantial foothold in the India market. Teva is rumored to be the lead suitor -- and is said to be trying for a third time -- perhaps a charm? It supposedly has a $6 B offer in mind, and its CEO has been on record recently as saying he is looking for more deals (of the right type). This is a bit ironic given that Teva is also closing 70+ manufacturing facilities -- though all that extra money needs to go somewhere. The second possible suitor mentioned is Mylan who again could use the products/sales and a the site in India. See Fierce Pharma.